MCID: PLS009
MIFTS: 65

Plasma Cell Neoplasm

Categories: Blood diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 11 28 14 16 71
Plasma Cell Dyscrasia 11 5 71
Paraproteinemias 43 71
Plasma Cells Dyscrasia 33
Plasma Cell Tumours 33
Plasma Cell Tumour 11
Plasmacytic Tumor 11
Multiple Myeloma 71
Plasmacytoma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:6536
MeSH 43 D010265
SNOMED-CT 68 71390001
UMLS 71 C0026764 C0030489 C0032131 more

Summaries for Plasma Cell Neoplasm

Disease Ontology: 11 A mature B-cell neoplasm that is composed of plasma cells.

MalaCards based summary: Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to plasma cell leukemia and myeloma, multiple. An important gene associated with Plasma Cell Neoplasm is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Coenzyme M and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are Decreased viability and Decreased shRNA abundance

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 32.8 FGFR3 DIS3 CDK4 B2M
2 myeloma, multiple 32.6 YAP1 TP53 TET2 NRAS MYD88 LIG4
3 myeloproliferative neoplasm 31.5 TET2 HRAS FLT3 FGFR3 DNMT3A B2M
4 polycythemia vera 31.3 TP53 TET2 IDH1 HRAS DNMT3A ATM
5 myelofibrosis 31.3 TP53 TET2 IDH1 HRAS FLT3 DNMT3A
6 smoldering myeloma 31.2 FGFR3 DIS3 CRBN B2M
7 monoclonal gammopathy of uncertain significance 31.0 TP53 MYD88 FGFR3 DIS3 CRBN B2M
8 myelodysplastic syndrome 31.0 TP53 TET2 NRAS KRAS IDH1 HRAS
9 lymphoma 30.9 TP53 TET2 MYD88 CDKN2C CDK4 ATM
10 leukemia, chronic lymphocytic 30.9 TP53 TET2 NRAS MYD88 KRAS HRAS
11 renal cell carcinoma, nonpapillary 30.8 TP53 NRAS KRAS HRAS FLT3 DNMT3A
12 leukemia 30.8 TP53 NRAS IDH1 FLT3 DNMT3A ATM
13 leukemia, chronic myeloid 30.8 TP53 TET2 NRAS KRAS HRAS FLT3
14 essential thrombocythemia 30.8 TP53 TET2 IDH1 FLT3 DNMT3A
15 leukemia, acute myeloid 30.7 TP53 TET2 NRAS KRAS IDH1 HRAS
16 carcinosarcoma 30.7 TP53 KRAS HRAS
17 lymphoma, non-hodgkin, familial 30.6 TP53 NRAS MYD88 FLT3 CDKN2C B2M
18 peripheral nervous system disease 30.6 TP53 NRAS KRAS HRAS CDK4 B2M
19 cholangiocarcinoma 30.6 YAP1 TP53 KRAS IDH1
20 glioblastoma 30.6 TP53 NRAS KRAS IDH1 HRAS DNMT3A
21 skin disease 30.6 TP53 NRAS MYD88 KRAS HRAS FGFR3
22 mantle cell lymphoma 30.6 TP53 MYD88 FLT3 CRBN CDKN2C CDK4
23 acute leukemia 30.5 KRAS FLT3 DNMT3A CDKN2C
24 poems syndrome 11.6
25 refractory plasma cell neoplasm 11.4
26 light chain deposition disease 11.3
27 immunoglobulin heavy chain amyloidosis 11.3
28 indolent plasma cell myeloma 11.1
29 polyneuropathy 10.8
30 blastoma 10.6 TP53 KRAS HRAS
31 serous cystadenocarcinoma 10.6 TP53 KRAS HRAS
32 vaginal carcinosarcoma 10.6 TP53 KRAS HRAS
33 cystadenocarcinoma 10.6 YAP1 TP53 KRAS
34 liver angiosarcoma 10.6 TP53 KRAS HRAS
35 cystadenofibroma 10.6 TP53 KRAS HRAS
36 endosalpingiosis 10.6 TP53 KRAS HRAS
37 appendix adenocarcinoma 10.6 TP53 KRAS HRAS
38 bladder transitional cell papilloma 10.6 TP53 HRAS FGFR3
39 large cell carcinoma with rhabdoid phenotype 10.6 TP53 KRAS HRAS
40 pancreatic signet ring cell adenocarcinoma 10.6 TP53 KRAS HRAS
41 blood protein disease 10.6 TP53 FGFR3 DIS3 B2M
42 signet ring cell adenocarcinoma 10.6 TP53 KRAS HRAS
43 biliary tract benign neoplasm 10.6 TP53 KRAS HRAS
44 pleomorphic carcinoma 10.6 TP53 KRAS HRAS
45 small intestine adenocarcinoma 10.6 TP53 KRAS HRAS
46 mismatch repair cancer syndrome 10.6 TP53 KRAS HRAS ATM
47 papillary adenoma 10.6 TP53 KRAS HRAS
48 acneiform dermatitis 10.6 NRAS KRAS HRAS
49 ovarian serous cystadenocarcinoma 10.6 TP53 NRAS KRAS HRAS B2M
50 lung carcinoma in situ 10.6 TP53 KRAS HRAS

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Disease Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

GenomeRNAi Phenotypes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

25 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.9 AURKA HRAS KRAS
2 Decreased viability GR00055-A-2 10.9 AURKA HRAS KRAS
3 Decreased viability GR00055-A-3 10.9 KRAS
4 Decreased viability GR00106-A-0 10.9 KRAS
5 Decreased viability GR00173-A 10.9 FLT3
6 Decreased viability GR00221-A-1 10.9 AURKA CYLD FGFR3 HRAS KRAS CDKN2C
7 Decreased viability GR00221-A-2 10.9 AURKA CYLD FGFR3 HRAS KRAS
8 Decreased viability GR00221-A-3 10.9 FGFR3 HRAS NRAS
9 Decreased viability GR00221-A-4 10.9 AURKA FLT3
10 Decreased viability GR00231-A 10.9 AURKA
11 Decreased viability GR00249-S 10.9 AURKA CYLD FGFR3 CDKN2C
12 Decreased viability GR00301-A 10.9 CYLD KRAS CDKN2C
13 Decreased viability GR00381-A-1 10.9 KRAS
14 Decreased viability GR00402-S-2 10.9 AURKA CYLD
15 Decreased shRNA abundance GR00251-A-1 10.36 B2M CDK4 CRBN CYLD FLT3 IDH1
16 Decreased shRNA abundance GR00251-A-2 10.36 B2M CDK4 CRBN CYLD FLT3 IDH1
17 no effect GR00402-S-1 10.15 ATM AURKA B2M CDK4 CDKN2C CRBN
18 no effect GR00402-S-2 10.15 ATM B2M CDK4 CDKN2C CRBN FGFR3
19 Decreased viability in pancreas lineage GR00235-A 9.56 DNMT3A FLT3 IDH1 TP53
20 Reduced mammosphere formation GR00396-S 9.5 ATM CDK4 DNMT3A HRAS KRAS MYD88
21 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 9.02 FLT3

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 ATM AURKA B2M CDK4 CDKN2C CRBN
2 homeostasis/metabolism MP:0005376 10.5 ATM B2M CDK4 CDKN2C CRBN CYLD
3 neoplasm MP:0002006 10.49 ATM AURKA B2M CDK4 CDKN2C CYLD
4 endocrine/exocrine gland MP:0005379 10.43 ATM AURKA B2M CDK4 CDKN2C CYLD
5 nervous system MP:0003631 10.42 ATM B2M CDK4 CDKN2C CRBN DNMT3A
6 cellular MP:0005384 10.4 ATM AURKA B2M CDK4 CDKN2C CYLD
7 immune system MP:0005387 10.39 ATM AURKA B2M CDK4 CDKN2C CRBN
8 behavior/neurological MP:0005386 10.33 ATM CDK4 CDKN2C CRBN CYLD DIS3
9 digestive/alimentary MP:0005381 10.29 B2M CDK4 CRBN CYLD FGFR3 HRAS
10 liver/biliary system MP:0005370 10.26 B2M CDK4 CRBN KRAS LIG4 MYD88
11 cardiovascular system MP:0005385 10.26 ATM B2M CDK4 CDKN2C CRBN HRAS
12 no phenotypic analysis MP:0003012 10.24 AURKA FGFR3 FLT3 HRAS KRAS MYD88
13 renal/urinary system MP:0005367 10.22 CDK4 CDKN2C FGFR3 HRAS KRAS MYD88
14 reproductive system MP:0005389 10.11 ATM AURKA B2M CDK4 CDKN2C DNMT3A
15 hematopoietic system MP:0005397 10.11 ATM AURKA B2M CDK4 CDKN2C CRBN
16 respiratory system MP:0005388 10.06 CDKN2C CYLD FGFR3 HRAS IDH1 KRAS
17 skeleton MP:0005390 10.06 AURKA CDK4 DNMT3A FGFR3 FLT3 HRAS
18 vision/eye MP:0005391 9.96 AURKA CDK4 CRBN DIS3 FGFR3 KRAS
19 mortality/aging MP:0010768 9.96 ATM AURKA B2M CDK4 CDKN2C CRBN
20 integument MP:0010771 9.4 ATM B2M CDK4 CDKN2C CYLD FGFR3

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 601)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coenzyme M Approved, Investigational Phase 4 3375-50-6 598 23662354
2
Phentolamine Approved Phase 4 50-60-2 5775
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
6
Iron Approved Phase 4 7439-89-6 29936
7
Pirarubicin Investigational Phase 4 72496-41-4 4844
8 Calcium, Dietary Phase 4
9
Epoetin Alfa Phase 4
10 Hematinics Phase 4
11 Chrysarobin Phase 4
12
Calcium Nutraceutical Phase 4 7440-70-2 271
13
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
14
Apixaban Approved Phase 3 503612-47-3 10182969
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
17
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
18
Amitriptyline Approved Phase 3 50-48-6 2160
19
Baclofen Approved Phase 3 1134-47-0 2284
20
Ketamine Approved, Vet_approved Phase 3 6740-88-1, 1867-66-9 3821
21
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
22
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
23
Pamidronic acid Approved Phase 3 40391-99-9 4674
24
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
25
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965
27
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
28
Deoxycholic acid Approved Phase 3 83-44-3 222528
29
Idarubicin Approved Phase 3 58957-92-9 42890
30
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
31
Sulfamethoxazole Approved Phase 3 723-46-6 5329
32
Ifosfamide Approved Phase 3 3778-73-2 3690
33
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
34
Vancomycin Approved Phase 3 1404-90-6 14969
35
Tazobactam Approved Phase 3 89786-04-9 123630
36
Piperacillin Approved Phase 3 66258-76-2 43672
37
Denosumab Approved Phase 3 615258-40-7
38
Epirubicin Approved Phase 3 56420-45-2 41867
39
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
40
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
41
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
42
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
43
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
44
Oxycodone Approved, Illicit, Investigational Phase 3 76-42-6 5284603
45
Morphine Approved, Investigational Phase 3 57-27-2 5288826
46
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8 9875401
47
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
48
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
49
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
50
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961

Interventional clinical trials:

(show top 50) (show all 3030)
# Name Status NCT ID Phase Drugs
1 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Unknown status NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
2 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
3 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Unknown status NCT04348006 Phase 4 Bortezomib 3.5 MG
4 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
5 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
6 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
7 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Completed NCT03768960 Phase 4 Daratumumab
9 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
10 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide
11 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
12 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
13 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Completed NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
14 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
15 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
16 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
17 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
18 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
19 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
20 Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma. Completed NCT00622505 Phase 4 zoledronic acid
21 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
22 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
23 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
24 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone;Daratumumab
25 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
26 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
27 Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel Recruiting NCT05201781 Phase 4 Cilta-cel
28 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
29 A Multi-center, Open-label, Single-arm Clinical Study of Ixazomib/Pomalidomide/Dexamethasone (IxaPD) in the Treatment of Patients With Relapsed Multiple Myeloma Recruiting NCT04989140 Phase 4 Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
30 A Single Arm, Open Label, Interventional Study Assessing the Mobilization Efficacy and Safety of Plerixafor in Combination With G- CSF in Multiple Myeloma Patients for Autologous Transplantation Recruiting NCT05087212 Phase 4 plerixafor + G-CSF
31 Influenza Vaccination in Plasma Cell Dyscrasias Active, not recruiting NCT04080531 Phase 4
32 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Active, not recruiting NCT02286830 Phase 4 Zoledronic acid
33 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Active, not recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
34 Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day: Reduction in Costs, Same Efficacy? A PKPD Bioequivalence Pilot Study; the POMAlternative Study Not yet recruiting NCT05555329 Phase 4 Pomalidomide 4 mg every day in cycle 1;Pomalidomide 4 mg every other day in cycle 2;Pomalidomide 2 mg every day in cycle 2;Pomalidomide 2 mg every day in cycle 3;Pomalidomide 4 mg every other day in cycle 3
35 A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Not yet recruiting NCT05545202 Phase 4
36 Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study Not yet recruiting NCT05429515 Phase 4 Chemotherapy
37 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
38 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
39 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
40 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Withdrawn NCT02920190 Phase 4 Liraglutide
41 An Open-Label, Non-Comparative, Two-Cohort, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Pomalidomide and Dexamethasone (IPd, Cohort A) or With Lenalidomide and Dexamethasone (IRd, Cohort B) in Patients With Relapsed/Refractory Multiple Myeloma Previously Receiving a Parenteral Proteasome Inhibitor-based Treatment Regimen (US MM-7) Withdrawn NCT05183139 Phase 4 Ixazomib;Pomalidomide;Lenalidomide;Dexamethasone
42 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
43 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
44 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
45 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
46 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
47 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
48 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
49 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
50 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Genetic tests related to Plasma Cell Neoplasm:

# Genetic test Affiliating Genes
1 Plasma Cell Neoplasm 28

Anatomical Context for Plasma Cell Neoplasm

Organs/tissues related to Plasma Cell Neoplasm:

MalaCards : T Cells, Bone Marrow, Bone, Nk Cells, Myeloid, Breast, Kidney

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 1649)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 5
19855393 2009
3
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 5
18642369 2008
4
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 5
16841094 2006
5
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 5
16752380 2006
6
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 5
15772091 2005
7
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 5
12833394 2003
8
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 5
12624096 2003
9
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 5
11529856 2001
10
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 5
10073901 1999
11
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 5
9677066 1998
12
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 5
9207791 1997
13
Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. 5
8858131 1996
14
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 5
7773297 1995
15
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. 62
36328595 2023
16
Extramedullary plasmacytoma of the uterine cervix arising in an asymptomatic 46-year-old female. 62
36277031 2022
17
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM). 62
36270091 2022
18
A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families. 62
36467798 2022
19
How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. 62
36450104 2022
20
LOCALIZED CONJUNCTIVAL AL-AMYLOID DEPOSITS SECONDARY TO A RETINAL DETACHMENT SURGERY RADIAL EXPLANT. 62
33229921 2022
21
A POEMS syndrome patient with idiopathic non-cirrhotic portal hypertension received the transjugular intrahepatic portosystemic shunt: a case report and literature review. 62
36412305 2022
22
Pediatric Plasma Cell Neoplasms: A Population-Based Study. 62
35941071 2022
23
FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome. 62
36132063 2022
24
Clinical Presentation and Outcome of Sinonasal Extraosseous Plasmacytoma in Denmark: A Nationwide Cohort From 1980 to 2017. 62
36433794 2022
25
Comprehensive Diagnosis and Management of POEMS Syndrome. 62
36340912 2022
26
Low-grade B-cell lymphoma of the central nervous system with plasmacytic differentiation and amyloid deposition. 62
36451532 2022
27
Coexistence of TEMPI syndrome and leukocytoclastic vasculitis successfully treated with autologous stem cell transplantation. 62
36467823 2022
28
Light Chain Amyloidosis Presenting as a Septic Shock: A Case Report and Review of Literature. 62
36381809 2022
29
An Analysis of M-protein in Plasma cell Dyscrasia Patients Identifies that IgG Lambda Subtype is More Commonly Associated with Normal Serum Free Light Chain (SFLC) Ratio. 62
36262785 2022
30
Two cases of extramedullary plasmacytoma of the small intestine presenting with ileus: A case report. 62
36221423 2022
31
Dual Expression of Immunoglobulin Light Chains in Plasma Cell Myeloma: A Case Report and Literature Review. 62
36314594 2022
32
Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. 62
36028388 2022
33
Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital. 62
35469400 2022
34
Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report. 62
36246794 2022
35
Epstein-Barr Virus-Positive Plasma Cell Neoplasm of Nasal Cavity in an Immunocompetent Adult. 62
35925565 2022
36
Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis. 62
35993812 2022
37
A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms. 62
35940519 2022
38
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms. 62
36244464 2022
39
Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. 62
35650679 2022
40
Long-Term Complete Clinical and Hematological Response With Bortezomib: The Report of a Case With TEM(P)I Syndrome and a Review of the Literature. 62
35624059 2022
41
18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple Myeloma. 62
35930716 2022
42
Testicular Plasmacytoma Masking as Epididymo-orchitis in a Known Multiple Myeloma Patient. 62
36060019 2022
43
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. 62
35731907 2022
44
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. 62
36075048 2022
45
Severe bleeding diathesis as onset of light-chain amyloidosis: combined excessive fibrinolysis and acquired von Willebrand disease in a young patient. 62
36165074 2022
46
The Prevalence of Epstein-Barr Virus in Plasma Cell Neoplasms is Higher in HIV-Positive Individuals. 62
35912479 2022
47
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. 62
35978321 2022
48
Multiple Myeloma Uncovered Under Excessive Antacid and Chronic NSAID Use in a Young Female. 62
36072215 2022
49
A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations. 62
35419626 2022
50
Evidence-based medical treatment of POEMS syndrome. 62
35934319 2022

Variations for Plasma Cell Neoplasm

ClinVar genetic disease variations for Plasma Cell Neoplasm:

5 (show top 50) (show all 196)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LIG4 NM_206937.2(LIG4):c.2440C>T (p.Arg814Ter) SNV Pathogenic
7673 rs104894419 GRCh37: 13:108861177-108861177
GRCh38: 13:108208829-108208829
2 FGFR3 NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu) SNV Pathogenic
16331 rs78311289 GRCh37: 4:1807889-1807889
GRCh38: 4:1806162-1806162
3 FGFR3 FGFR3, FGFR3/IGH FUSION VAR Pathogenic
16343 GRCh37:
GRCh38:
4 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic
45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
5 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic
Likely Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
6 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic/Likely Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
7 TP53 NM_000546.6(TP53):c.841G>A (p.Asp281Asn) SNV Likely Pathogenic
376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
8 TP53 NM_000546.6(TP53):c.818G>C (p.Arg273Pro) SNV Likely Pathogenic
231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
9 TP53 NM_000546.6(TP53):c.743G>C (p.Arg248Pro) SNV Likely Pathogenic
237954 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
10 TP53 NM_000546.6(TP53):c.613T>C (p.Tyr205His) SNV Likely Pathogenic
376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
11 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
12 TP53 NM_000546.6(TP53):c.824G>A (p.Cys275Tyr) SNV Likely Pathogenic
215997 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
13 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
14 TP53 NM_000546.6(TP53):c.713G>T (p.Cys238Phe) SNV Likely Pathogenic
376574 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
15 PTPN11 NM_002834.5(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely Pathogenic
13336 rs121918464 GRCh37: 12:112888210-112888210
GRCh38: 12:112450406-112450406
16 TP53 NM_000546.6(TP53):c.395A>G (p.Lys132Arg) SNV Likely Pathogenic
376625 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
17 TP53 NM_000546.6(TP53):c.421T>C (p.Cys141Arg) SNV Likely Pathogenic
376565 rs1057519978 GRCh37: 17:7578509-7578509
GRCh38: 17:7675191-7675191
18 TP53 NM_000546.6(TP53):c.423C>G (p.Cys141Trp) SNV Likely Pathogenic
376564 rs1057519977 GRCh37: 17:7578507-7578507
GRCh38: 17:7675189-7675189
19 TP53 NM_000546.6(TP53):c.842A>G (p.Asp281Gly) SNV Likely Pathogenic
141141 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
20 BRAF NM_004333.6(BRAF):c.1787G>T (p.Gly596Val) SNV Likely Pathogenic
40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
21 TP53 NM_000546.6(TP53):c.742C>G (p.Arg248Gly) SNV Likely Pathogenic
376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
22 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
23 TP53 NM_000546.6(TP53):c.394A>G (p.Lys132Glu) SNV Likely Pathogenic
376626 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
24 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely Pathogenic
12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
25 CDK4 NM_000075.4(CDK4):c.70C>T (p.Arg24Cys) SNV Likely Pathogenic
16928 rs11547328 GRCh37: 12:58145431-58145431
GRCh38: 12:57751648-57751648
26 TP53 NM_000546.6(TP53):c.833C>A (p.Pro278His) SNV Likely Pathogenic
376646 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
27 TP53 NM_000546.6(TP53):c.815T>G (p.Val272Gly) SNV Likely Pathogenic
233323 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
28 TP53 NM_000546.6(TP53):c.451C>G (p.Pro151Ala) SNV Likely Pathogenic
376641 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
29 TP53 NM_000546.6(TP53):c.585C>G (p.Ile195Met) SNV Likely Pathogenic
376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
30 TP53 NM_000546.6(TP53):c.832C>A (p.Pro278Thr) SNV Likely Pathogenic
376643 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
31 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Likely Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
32 TP53 NM_000546.6(TP53):c.613T>A (p.Tyr205Asn) SNV Likely Pathogenic
376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
33 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
34 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
35 TP53 NM_000546.6(TP53):c.712T>G (p.Cys238Gly) SNV Likely Pathogenic
376577 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
36 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
37 TP53 NM_000546.6(TP53):c.451C>A (p.Pro151Thr) SNV Likely Pathogenic
12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
38 TP53 NM_000546.6(TP53):c.583A>T (p.Ile195Phe) SNV Likely Pathogenic
376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
39 TP53 NM_000546.6(TP53):c.587G>C (p.Arg196Pro) SNV Likely Pathogenic
231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
40 TP53 NM_000546.6(TP53):c.818G>T (p.Arg273Leu) SNV Likely Pathogenic
376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
41 TP53 NM_000546.6(TP53):c.832C>G (p.Pro278Ala) SNV Likely Pathogenic
376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
42 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
43 TP53 NM_000546.6(TP53):c.713G>A (p.Cys238Tyr) SNV Likely Pathogenic
182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
44 TP53 NM_000546.6(TP53):c.422G>A (p.Cys141Tyr) SNV Likely Pathogenic
140801 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
45 TP53 NM_000546.6(TP53):c.743G>T (p.Arg248Leu) SNV Likely Pathogenic
230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
46 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely Pathogenic
12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
47 TP53 NM_000546.6(TP53):c.614A>G (p.Tyr205Cys) SNV Likely Pathogenic
376681 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
48 TP53 NM_000546.6(TP53):c.843C>G (p.Asp281Glu) SNV Likely Pathogenic
376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
49 TP53 NM_000546.6(TP53):c.814G>A (p.Val272Met) SNV Likely Pathogenic
185814 rs121912657 GRCh37: 17:7577124-7577124
GRCh38: 17:7673806-7673806
50 TP53 NM_000546.6(TP53):c.824G>C (p.Cys275Ser) SNV Likely Pathogenic
376583 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796

Copy number variations for Plasma Cell Neoplasm from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TP53 NRAS KRAS HRAS FLT3 FGFR3
2 13.8 CDK4 CYLD FGFR3 FLT3 HRAS KRAS
3
Show member pathways
13.72 TP53 NRAS KRAS HRAS FLT3 FGFR3
4
Show member pathways
13.47 ATM CDK4 CDKN2C FGFR3 HRAS KRAS
5
Show member pathways
13.43 YAP1 TP53 NRAS MYD88 KRAS HRAS
6
Show member pathways
13.43 ATM B2M CDK4 CRBN DNMT3A FGFR3
7
Show member pathways
13.36 TP53 NRAS MYD88 KRAS HRAS FLT3
8
Show member pathways
12.91 TP53 NRAS KRAS HRAS FLT3 FGFR3
9 12.84 YAP1 NRAS KRAS HRAS FLT3 FGFR3
10
Show member pathways
12.78 TP53 NRAS MYD88 KRAS HRAS CYLD
11
Show member pathways
12.74 NRAS KRAS HRAS FLT3 FGFR3
12
Show member pathways
12.7 TP53 NRAS KRAS HRAS FGFR3 CDK4
13
Show member pathways
12.66 TP53 NRAS KRAS HRAS FGFR3 ATM
14
Show member pathways
12.63 YAP1 TP53 NRAS KRAS HRAS
15
Show member pathways
12.53 TP53 NRAS KRAS HRAS
16 12.48 YAP1 TP53 HRAS FLT3 FGFR3 CDK4
17 12.44 ATM AURKA CDK4 CDKN2C LIG4 TP53
18
Show member pathways
12.42 NRAS KRAS HRAS FLT3 FGFR3
19 12.42 TP53 NRAS KRAS HRAS FGFR3
20
Show member pathways
12.38 NRAS KRAS HRAS FLT3 FGFR3
21
Show member pathways
12.32 TP53 NRAS KRAS HRAS FGFR3 ATM
22
Show member pathways
12.31 NRAS KRAS HRAS FGFR3
23
Show member pathways
12.29 TP53 CDKN2C CDK4 ATM
24
Show member pathways
12.25 FGFR3 HRAS KRAS NRAS
25
Show member pathways
12.23 TP53 NRAS KRAS HRAS FGFR3 CDK4
26
Show member pathways
12.22 TP53 NRAS KRAS HRAS
27
Show member pathways
12.21 NRAS KRAS HRAS FGFR3
28 12.21 FGFR3 FLT3 HRAS KRAS NRAS
29
Show member pathways
12.2 NRAS KRAS HRAS CDK4
30
Show member pathways
12.19 TP53 MYD88 HRAS CDK4
31
Show member pathways
12.17 FLT3 HRAS KRAS NRAS
32
Show member pathways
12.15 TP53 CDKN2C CDK4 ATM
33
Show member pathways
12.14 TP53 NRAS KRAS HRAS FGFR3 CDK4
34
Show member pathways
12.1 YAP1 NRAS KRAS HRAS
35 12.1 TP53 KRAS CDK4 AURKA ATM
36
Show member pathways
11.93 NRAS KRAS HRAS
37
Show member pathways
11.92 NRAS KRAS HRAS
38
Show member pathways
11.92 YAP1 TP53 ATM
39
Show member pathways
11.9 NRAS KRAS HRAS
40
Show member pathways
11.88 HRAS KRAS NRAS
41
Show member pathways
11.86 NRAS KRAS HRAS
42
Show member pathways
11.81 NRAS KRAS HRAS
43 11.79 TP53 MYD88 FGFR3
44
Show member pathways
11.79 HRAS KRAS NRAS TP53
45
Show member pathways
11.78 FLT3 HRAS KRAS NRAS
46 11.77 ATM HRAS KRAS NRAS TP53
47
Show member pathways
11.75 NRAS KRAS HRAS B2M
48 11.71 TP53 HRAS ATM
49
Show member pathways
11.7 HRAS KRAS NRAS
50 11.69 TP53 CDKN2C CDK4

GO Terms for Plasma Cell Neoplasm

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.29 YAP1 KRAS HRAS FLT3 FGFR3 CDK4
2 positive regulation of gene expression GO:0010628 10.28 YAP1 TP53 MYD88 KRAS HRAS ATM
3 MAPK cascade GO:0000165 10.13 NRAS KRAS HRAS FGFR3
4 T cell differentiation in thymus GO:0033077 9.97 B2M LIG4 TP53
5 Ras protein signal transduction GO:0007265 9.97 TP53 NRAS KRAS HRAS
6 fibroblast proliferation GO:0048144 9.95 TP53 LIG4 HRAS
7 cell population proliferation GO:0008283 9.95 CDKN2C KRAS LIG4 TP53 YAP1
8 cell cycle GO:0007049 9.93 ATM AURKA CDK4 CDKN2C CYLD LIG4
9 response to ionizing radiation GO:0010212 9.91 ATM DNMT3A LIG4
10 phosphorylation GO:0016310 9.91 FLT3 FGFR3 CDKN2C CDK4 AURKA ATM
11 regulation of cell population proliferation GO:0042127 9.8 YAP1 TP53 MYD88 HRAS FLT3
12 stem cell proliferation GO:0072089 9.8 YAP1 TP53 LIG4 CDKN2C
13 pro-B cell differentiation GO:0002328 9.76 LIG4 FLT3
14 cellular response to gamma radiation GO:0071480 9.56 YAP1 TP53 HRAS ATM
15 neuron apoptotic process GO:0051402 9.32 TP53 LIG4 KRAS HRAS ATM

Molecular functions related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein activity GO:0003925 9.63 NRAS KRAS HRAS
2 kinase activity GO:0016301 9.43 FLT3 FGFR3 CDKN2C CDK4 AURKA ATM
3 nucleotide binding GO:0000166 9.28 NRAS LIG4 KRAS HRAS FLT3 FGFR3

Sources for Plasma Cell Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....